The invention relates to a group of tumor-targeting-medicine Combretastatin A4 derivatives of imidazoles, oxazoles and thiazoles with A rings containing 4 substituted 3, 5-dimethoxyphenyl groups, phosphates, sulfonates or pharmaceutically-accepted salts, glycoside derivatives and solvates thereof. Proved by a pharmacological-activity screening test, the compound disclosed by the invention has better in-vitro anti-tumor activity and good microtubulin inhibiting effect.